| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
As an economic evaluation of tailor-made diagnostic technologies for breast cancer care, a cost-effectiveness study was conducted regarding an introduction of the 95-gene assay for the primary breast cancer into the benefit package of the National Health Insurance. The assay was targeted because it had been developed to the stage of diffusion in Japan. Changes of the treatment decision whether undergoing adjuvant chemotherapy or not according to validation case series for the development of the assay were applied for an economic Markov model of breast cancer care. An incremental cost-effectiveness ratio of including the assay into the benefit package was estimated at \4,754,269 in order to gain 1 quality adjusted life year. It was less than the threshold of social willingness-to-pay for new health care, \5,000,000, which suggested that making the assay available under the National Health Insurance was justifiable.
|
